readthroughSign in
CompanyVORNasdaqBoston, MA

Vor Biopharma

Vor Biopharma develops telitacicept, a dual-target fusion protein for autoimmune diseases.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 12Latest story